Rajasthan

About Authors:
Jatin  Patel^1*, Prof. Rajesh Kumar Dholpuria², Dhiren Shah^1
2(Professor, Head of Department of pharmacognosy),
¹Seth G.L. Bihani S.D. College of Technical Education,
Institute of Pharmaceutical Sciences and Drug Research,
Sri Ganganagar, Rajasthan, INDIA
*Patelj313@yahoo.in

ABSTRACT
Patent Right varies from country to country. In India the law which govern patent right is "Indian Patent Act 1970". Indian Patent Act, 1970 grants exclusive right to the inventor for his invention for limited period of time. Generally 20 years time has been granted to the patent holder but in case of inventions relating to manufacturing of food or drugs or medicine it is for seven years from the date of patent. There is certain legal procedure which needs to be followed in order to register. There are several attorney helping inventor in patent registration by providing them best well informed knowledge. In India patent registration can be filed individually or jointly. In case of deceased inventor this can be done his legal representative on behalf of him. All the required documents need to be filed along with the application form. Only after verification registration certificate is provided to the applicant.

About Authors:
*Tarun Patel, Prof. Dr. Vipin Kukkar, Krunal Parik
Seth G.L. Bihani S.D. College of Technical Education,
Institute of Pharmaceutical Sciences and Drug Research,
Sri Ganganagar, Rajasthan, INDIA
*tarunpatel35@gmail.com

ABSTRACT:
In pharma industry Packaging and Labelling plays very important role for improvements of attraction to human beings. So by improving our packaging and labeling style we can easily improve our product market value. Green packaging is also an alternative to make packaging more environmental friendly which would not affect the nature in any way. The most desirable solution is “use less, discard less, save more, reuse more”In this review article we discuss briefly about the requirement of packaging and labeling control of product according to different GMPs.

[adsense:336x280:8701650588]

About Authors:
Mr. Satyanand Tyagi*, Patel Chirag J¹, Devesh Kaushik²
*President, Tyagi Pharmacy Association & Scientific Writer (Pharmacy), Chattarpur, New Delhi, India-110074.
Prof. Satyanand Tyagi is a life time member of various pharmacy professional bodies like IPA, APTI and IPGA. He has published various research papers and review articles. His academic work includes 60 Publications (50 Review Articles, 08 Research Articles and 02 Short Communications of Pharmaceutical, Medicinal and Clinical Importance, published in standard and reputed National and International Pharmacy journals; Out of 60 publications, 11 are International Publications).
He has published his papers almost in different specialization of Pharmacy field...His research topics of interest are neurodegenerative disorders, diabetes mellitus, cancer, rare genetic disorders, psycho-pharmacological agents as well as epilepsy.
¹Department of Pharmaceutics, Maharishi Arvind Institute of Pharmacy, Mansarovar, Jaipur, Rajasthan, India-302020.
²Territory Business Manager, Diabetes Division, Abbott Healthcare Private Limited, Okhla, New Delhi, India- 110020.
*sntyagi9@yahoo.com, +91-9871111375/9582025220

ABSTRACT:
A group of Australian researchers at the Garvan Institute in Sydney have conducted a study indicating how Grb10 protein plays a crucial role in increasing muscle mass during development. Growth factor receptor-bound protein 10 also known as insulin receptor-binding protein Grb-IR is a protein that in humans is encoded by the GRB10 gene. The product of this gene belongs to a small family of adapter proteins that are known to interact with a number of receptor tyrosine kinases and signaling molecules. This gene encodes a growth factor receptor-binding protein that interacts with insulin and insulin-like growth-factor receptors (e.g., IGF1R and IGF2R). Over expression of some isoforms of the encoded protein inhibits tyrosine kinase activity and results in growth suppression. This gene is imprinted in a highly isoform- and tissue-specific manner. Alternatively spliced transcript variants encoding different isoforms have been identified.Scientists have discovered a way to build bigger and stronger muscles without having to lift a finger.

About Authors:
Patel Chirag J^1*, Satyanand Tyagi², Patel Jaimin^1
1Maharishi Arvind Institute of Pharmacy, Department of Pharmaceutics, Jaipur, Rajasthan.
²President, Tyagi Pharmacy Association & Scientific Writer (Pharmacy), Chattarpur, New Delhi, India.
*chirag.bangalore@gmail.com, +918000501871

ABSTRACT:
Now a day about 74% of drugs are taken orally and are found not to be as effective as desired either due to bioavailability problems or degradation of drug in acidic pH of stomach. To resolve such problems, transdermal drug delivery system (TDDS) was emerged. Transdermal drug delivery systems are dosage forms involves drug transport to viable epidermal and dermal tissues of the skin for local therapeutic effect while a very major fraction of drug is transported into the systemic blood circulation. Transdermal drug delivery systems, also known as ‘‘patches,’’ are dosage forms designed to deliver a therapeutically effective amount of drug across a patient’s skin. This review article provides an overview of TDDS, advantages, limitations, various components of TDDS, methods of preparation, types of transdermal patches, factors affecting transdermal permeation, evaluation parameters and new approaches in TDDS.

[adsense:336x280:8701650588]

About Authors:
Arshad Hala*, Prof. Rajesh Dholpuria, Nilesh Sovasia
¹Seth G. L. Bihani S. D. College Of Technical Education,
Institute Of Pharmaceutical Sciences & Drug Research,
Gaganpath, Sri Ganganagar, Rajasthan 335001
*Arshad_hala@yahoo.com

1. INTRODUCTION:-
1.1. Origin:-
Contract manufacturing is defined as the manufacture (or partial manufacturer) of a product to the order of one person or organization (the contract giver or customer) by another independent person or organization (contract acceptor or principle manufacturer). Manufacture in this context is identified as the act of processing or packaging a medicinal product or device to a given specification.(Shah, D.H., 2000)

Contract manufacturing should be consideration as an extension of the principal manufacturer’s operation. Consequently the principal manufacturer should require the same standards of good manufacturing practices (GMP) for a contractor’s operation as he would his own. In addition, the customer must ensure that the principle manufacturer holds the relevant legal authorizations for the work to be carried out.(Shah, D.H., 2000)

The responsibility and activities undertaken by each party need to be clearly stated in a formal agreement, separate from but additional to the legal business contract formed by the placement of an order. Commercial matters need to be appreciated as being distinct from technical matter and need to be detailed separately with due consideration for compliance with local legislation.(Shah, D.H., 2000)

About Authors:
Patel Chirag J^1*, Satyanand Tyagi^2
1Maharishi Arvind Institute of Pharmacy, Department of Pharmaceutics, Jaipur, Rajasthan.
²President, Tyagi Pharmacy Association & Scientific Writer (pharmacy), Chattarpur, New Delhi, India.
*chirag.bangalore@gmail.com, +918000501871

ABSTRACT
The basic rationale of sustained release drug delivery system optimizes the biopharmaceutical, pharmacokinetic and pharmacodynamic properties of a drug in such a way that its utility is maximized, side-effects are reduced and cure of the disease is achieved. There are several advantages of sustained release drug delivery over conventional dosage forms like improved patient compliance due to less frequent drug administration, maximum utilization of the drug, increased safety margin of potent drug, reduction of fluctuation in steady-state drug levels, reduction in healthcare costs through improved therapy and shorter treatment period.Presently pharmaceutical industries are focusing on development of sustained release formulations due to its inherent boons.Wide varieties of polymers are available for retarding the release rate of drugs hence sustains the action of drugs. This article contains the basic information regarding sustained-release formulation, its advantages, different types, and characteristics involved in oral sustained-release dosage form design.

About Authors:
Mr. Satyanand Tyagi*, Patel Chirag J¹, Asheesh Singh²
*President, Tyagi Pharmacy Association & Scientific Writer (pharmacy), Chattarpur, New Delhi, India-110074.
Prof. Satyanand Tyagi is a life time member of various pharmacy professional bodies like IPA, APTI and IPGA. He has published various research papers and review articles. His academic works include 52 Publications (44 Review Articles and 08 Research Articles of Pharmaceutical, Medicinal and Clinical Importance, published in standard and reputed National and International Pharmacy journals; Out of 52 publications, 11 are International Publications).
He has published his papers almost in different specialization of Pharmacy field...His research topics of interest are neurodegenerative disorders, diabetes mellitus, cancer, rare genetic disorders, psycho-pharmacological agents as well as epilepsy.
¹Department of Pharmaceutics, Maharishi Arvind Institute of Pharmacy, Mansarovar, Jaipur, Rajasthan, India-302020.
²Research Associate, Center for Research and Development, Ipca Laboratories Ltd Ratlam, Madhya Pradesh, India-457114.
*sntyagi9 @yahoo.com, +91-9871111375 / 9582025220

ABSTRACT:
Prior studies have suggested that depressed people with evidence of high inflammation are less likely to respond to traditional treatments for the disorder, including anti-depressant medications and psychotherapy. This study was designed to see whether blocking inflammation would be a useful treatment for either a wide range of people with difficult-to-treat depression or only those with high levels of inflammation. The study employed infliximab, one of the new biologic drugs used to treat autoimmune and inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. A biologic drug copies the effects of substances naturally made by the body's immune system. In this case, the drug was an antibody that blocks tumour necrosis factor (TNF), a key molecule in inflammation that has been shown to be elevated in some depressed individuals. Study participants all had major depression and were moderately resistant to conventional antidepressant treatment. Each participant was assigned either to infliximab or to a non-active placebo treatment. When investigators looked at the results for the group as a whole, no significant differences were found in the improvement of depression symptoms between the drug and placebo groups. However, when the subjects with high inflammation were examined separately, they exhibited a much better response to infliximab than to placebo.